Publisher -

A number of Bollywood celebrities had been snapped on the airport late final night time. Amongst these clicked by the paparazzi was Deepika Padukone. The actress was seen in a comfortable but stylish off…

Michael Vi/iStock Editorial through Getty Photos Regardless of reporting better-than-expected financials for Q3 2022, Veeva Methods (NYSE:VEEV) dropped ~5% pre-market Friday after the cloud-based software program resolution supplier…

Play video content material…

Volkswagen printed numerous revealing teaser sketches for the upcoming ID.3, whereas asserting its debut for spring 2023. The compact EV will profit from minor styling modifications, improved high quality with animal-free supplies…

Visa executives have acquired thousands and thousands of {dollars} in bonuses this 12 months regardless of lacking an important efficiency goal that the corporate mentioned it may have met had been it not for the struggle in…

Brazil’s Comedian Con Expertise (CCPX 2022) is formally underway, the place Pedro Pascal is lighting up the primary stage with particulars about The Mandalorian Season 3. Returning to São Paulo for the primary in-person model of the…

Within the final week or so, an internet app named Instafest went viral. Instafest permits you to generate pageant posters out of your Spotify listening historical past. Tens of millions of individuals began…

(Bloomberg) -- Inventory buyers’ optimism round a cooling labor market and a Federal Reserve pivot is overdone, in line with Financial institution of America Corp. strategists, who advocate promoting the rally forward of a possible surge…

Producers Rohit Shetty Productionz, T-Sequence Movies and Reliance Leisure have launched the primary trailer for keenly-anticipated comedy movie “Cirkus.” That includes Ranveer Singh and Varun Sharma in twin roles, the…

koto_feja Anavex Life Sciences (NASDAQ:AVXL) mentioned its oral drug ANAVEX2-73 (blarcamesine) met the principle objective of enchancment in cognitive perform in sufferers with early Alzheimer's illness (AD) in a part 2B/3 trial.…